ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-OR19

Calprotectin Is Associated with Vascular Calcification and Cardiovascular Complications During CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2303 CKD (Non-Dialysis): Mechanisms


  • Klein, Julie, Inserm U1297, Toulouse, France
  • Amaya-Garrido, Ana, Inserm U1297, Toulouse, France
  • Brunet, Manon, Inserm U1297, Toulouse, France
  • Buffin-Meyer, Benedicte, Inserm U1297, Toulouse, France
  • Del Bello, Arnaud, Centre Hospitalier Universitaire de Toulouse, Toulouse, Occitanie, France
  • Ardeleanu, Serban, Association pour l'Utilisation du Rein Artificiel a la Reunion, Saint-Gilles-les-Bains, Réunion
  • Voelkl, Jakob, Johannes Kepler Universitat Linz, Linz, Austria
  • Glorieux, Griet Lrl, Universiteit Gent, Gent, Belgium
  • Kublickiene, Karolina, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Stenvinkel, Peter, Karolinska Institutet, Stockholm, Stockholm, Sweden
  • Faguer, Stanislas, Centre Hospitalier Universitaire de Toulouse, Toulouse, Occitanie, France
  • Valdivielso, Jose M., Institut de Recerca Biomedica de Lleida Fundacio Dr Pifarre, Lleida, Catalunya, Spain
  • Schanstra, Joost, Inserm U1297, Toulouse, France

In patients with chronic kidney disease (CKD), vascular calcification is considered a major risk factor of cardiovascular (CV) mortality. The mechanisms of vascular calcification are complex and treatment options remain limited. Serum proteome analysis could help identify novel actors and potential therapeutic targets.


In this observational, European, multicenter study, we included 112 CKD3-4 patients from Spain, 171 dialysis patients from Toulouse and La Reunion (France), and 170 CKD5 patients from Sweden. Serum proteome analysis was performed using LC-MS/MS on a subset of 66 CKD3-4 patients. Circulating calprotectin concentration was validated in the serum or plasma from the full cohorts by ELISA. Calprotectin was associated with CV outcome (2-4 years of follow-up) or with vascular calcification score assessed by Von Kossa staining on a piece of epigastric artery collected during renal transplantation surgery. The effect of calprotectin on calcification was measured in primary human vascular smooth muscle cells (VSMCs) and mouse aortic rings. The anticalcific potential of calprotectin inhibitor paquinimod was studied in a 5/6 subtotal nephrectomy mouse model.


We identified using serum proteome analysis and further validation by ELISA that calprotectin, a circulating damage-associated molecular pattern protein, was associated with vascular calcification, CV outcome and mortality in CKD and dialysis patients. In primary human VSMCs and mouse aortic rings, calprotectin exacerbated calcification. Treatment with paquinimod inhibited the pro-calcifying effect of calprotectin. Paquinimod also ameliorated calcification induced by serum of uremic patients in primary human VSMCs. Finally, treatment with paquinimod blocked vascular calcification in mice with chronic renal failure induced by 5/6 subtotal nephrectomy.


We identified calprotectin as a key factor associated with vascular calcification, CV outcome and mortality in CKD patients. Blockade of calprotectin by paquinimod might be a promising strategy to reduce the burden of vascular calcification in CKD.